Twist Bioscience Corporation, a leading player in the life sciences sector, announced the launch of the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel. This new research-use-only solution is designed to help scientists and clinicians detect genomic alterations across a broad range of tumors, accelerate targeted therapy development, and strengthen clinical as well as translational oncology research.
“We designed this panel to break the status quo in genomic profiling by offering laboratories a powerful alternative to locked, one-size-fits-all solutions,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “With our customizable content, flexible workflow, and compatibility with multiple sequencing platforms, Twist’s Oncology DNA CGP Panel puts scientific control back in the hands of researchers and clinicians, particularly for those who need a more cost-effective solution compared to existing CGP products or a more efficient option than smaller panels.”
Also Read: Trinity Life Sciences Unveils Digital Affinity for HCP Engagement
The Oncology DNA CGP Panel is tailored to meet the needs of regional clinical laboratories, academic medical centers, and biopharma partners. It features an updated biomarker list that spans 562 genes covering all major tumor types. With this extensive coverage, the panel enables detection of multiple genomic alterations and signatures, including base substitutions, insertions and deletions (indels), copy number variations (CNVs), gene rearrangements, as well as tumor mutational burden (TMB) and microsatellite instability (MSI).
To further streamline research workflows, the panel is paired with Twist’s high-quality, easy-to-use library preparation and target enrichment solutions. In addition, Twist is partnering with leading analytics companies to deliver an end-to-end offering from sequencing through analysis, ensuring researchers have the tools needed to accelerate discoveries in oncology.